HLA-A and neoplasm: Recently, a murine model system was developed that circumvents this limitation by using an HLA-A*02:01-transgenic murine GBM tumour cell line, which can be transfected with human TAAs and implanted intracranially into immunocompetent HLA-A*02:01-transgenic mice [46].